Menarini, Stemline, and MEDSIR Unveil Groundbreaking ADELA Trial for Advanced ER+/HER2- Breast Cancer at SABCS 2024

The Menarini Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. ("Stemline"), a wholly-own...

December 16, 2024 | Monday | News
Eli Lilly's Omvoh® (Mirikizumab) Receives Positive CHMP Opinion for Crohn’s Disease in the EU

Eli Lilly and Company (NYSE: LLY) announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human ...

December 16, 2024 | Monday | News
AstraZeneca and Merck Announce Six-Year Data from OlympiA Trial, Showing LYNPARZA Significantly Improves Survival in BRCA-Mutated Early Breast Cancer

 AstraZeneca and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced long-term results from the OlympiA Phase 3 trial w...

December 13, 2024 | Friday | News
Shaping Biopharma Purification: Phenomenex’s Vision for 2025

Matt Boag, Biopharmaceutical Product Marketing Manager at Phenomenex, discusses the transformative innovations shaping plasmid DNA, mRNA, and peptide purif...

December 12, 2024 | Thursday | Opinion
Lilly’s Pirtobrutinib Shows Strong Efficacy in Phase 3 BRUIN CLL-321 Trial for BTK-Inhibitor Pre-Treated CLL/SLL Patients

Eli Lilly and Company (NYSE: LLY) announced results from the Phase 3 BRUIN CLL-321 trial evaluating pirtobrutinib, a non-covalent (reversible) Bruton'...

December 10, 2024 | Tuesday | News
Merck's KEYTRUDA® Combined with LYNPARZA® Achieves Key Milestone in Phase 3 Trial for Advanced Ovarian Cancer

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that the Phase 3 KEYLYNK-001 trial evaluating KEYTRUDA ® (...

December 10, 2024 | Tuesday | News
Merck’s Zilovertamab Vedotin Achieves 100% Complete Response in Phase 2 DLBCL Trial, Setting Stage for Phase 3

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced the first presentation of data from the Phase 2 waveLINE-007 trial evalu...

December 09, 2024 | Monday | News
Kite Presents Groundbreaking Real-World Data at ASH, Showcasing Yescarta®'s Impact on Relapsed/Refractory Large B-Cell Lymphoma

Kite, a Gilead Company (Nasdaq: GILD), announced findings from three new analyses for Yescarta ® (axicabtagene ciloleucel) that demonstrate i...

December 09, 2024 | Monday | News
Genentech Presents Positive Five-Year Follow-Up Data from POLARIX Study on Polivy® Combination for Untreated DLBCL

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced data from a five-year follow-up of the pivotal Phase III POLARIX study evalu...

December 09, 2024 | Monday | News
Dewpoint Therapeutics and Mitsubishi Tanabe Pharma Partner to Advance Groundbreaking ALS Therapy

- Both companies will collaborate to advance a small molecule condensate modulator targeting TDP-43, with the potential to address the underlying patholo...

December 05, 2024 | Thursday | News
OmniScience and INmune Bio Join Forces to Transform Global Alzheimer’s Trial Operations with GenAI-Powered Data Platform

OmniScience and INmune Bio announced a pioneering partnership to revolutionize operations for INmune Bio’s global Phase 2 Alzheimer&...

December 05, 2024 | Thursday | News
Thermo Fisher Launches Innovative CTS™ Detachable Dynabeads™ to Redefine T Cell Therapy Manufacturing

T cell isolation and controlled release delivers flexibility and control in process development, clinical trials and commercial manufacturing  Ther...

December 05, 2024 | Thursday | News
Nxera Pharma Launches Phase 3 Trial of QUVIVIQ™ (Daridorexant) in South Korea to Address Insomnia Epidemic

Daridorexant is a dual orexin receptor antagonist being developed by Nxera for the treatment of adult patients with insomnia QUVIVIQ™ (daridorex...

December 05, 2024 | Thursday | News
LG AI Research Leverages AWS to Accelerate Cancer Diagnosis with EXAONEPath Pathology Model

At AWS re:Invent, Amazon Web Services (AWS), an Amazon.com, Inc. company (NASDAQ: AMZN),  announced that LG AI Research, the artificial intelligence (...

December 04, 2024 | Wednesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close